Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services ConferenceNyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastNyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle EastFirst patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates
Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandNyxoah Announces Commercial Launch of Genio® Innovative Therapy in EnglandFirst patients implanted with Genio at UCLH, London
Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference
Nyxoah Appoints John Landry as Chief Financial OfficerNyxoah Appoints John Landry as Chief Financial Officer
Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024Nyxoah to Release Third Quarter 2024 Financial Results on November 6, 2024
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational UpdateDREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Nyxoah to Participate in Upcoming Investor ConferencesNyxoah to Participate in Upcoming Investor Conferences
Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea DeviceNyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024
Nyxoah Appoints Scott Holstine as Chief Commercial OfficerNyxoah Appoints Scott Holstine as Chief Commercial Officer
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDANyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA
Nyxoah to Participate in the Jefferies Global Healthcare ConferenceNyxoah to Participate in the Jefferies Global Healthcare Conference
Nyxoah Announces Pricing of OfferingREGULATED INFORMATIONINSIDE INFORMATION
Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024Nyxoah to Release First Quarter 2024 Financial Results on May 14, 2024
Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationNyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationFirst medical device company to become a corporate champion at the ENTerprise Circle level
Nyxoah Announces DREAM U.S. Pivotal Study Meets Primary EndpointsNyxoah Announces DREAM U.S. Pivotal Study Meets Primary Endpoints
Nyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsNyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsExpect to report DREAM U.S. pivotal study efficacy and safety data by early AprilAchieved record quarterly sales of €1.8 million
Nyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceNyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024Nyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024
Nyxoah Announces 2024 Strategic PrioritiesNyxoah Announces 2024 Strategic Priorities
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®
Nyxoah Strengthens its Executive Leadership TeamNyxoah Strengthens its Executive Leadership TeamFrancis Kim appointed as Chief Regulatory and Quality Officer
Nyxoah to Participate in the Piper Sandler 35th Annual Healthcare ConferenceNyxoah to Participate in the Piper Sandler 35th Annual Healthcare Conference
Nyxoah Reports Third Quarter 2023 Financial and Operating ResultsNyxoah Reports Third Quarter 2023 Financial and Operating ResultsPartners with ResMed Germany to increase OSA awareness and therapy penetration
Nyxoah to Participate in the Jefferies London Healthcare ConferenceNyxoah to Participate in the Jefferies London Healthcare Conference
Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023Nyxoah to Release Third Quarter 2023 Financial Results on November 8, 2023
Nyxoah Announces Partnership with ResMed in GermanyNyxoah Announces Partnership with ResMed in GermanyCreates a continuum of care in the German obstructive sleep apnea market
Nyxoah to Participate in the Cantor Fitzgerald Global Healthcare ConferenceNyxoah to Participate in the Cantor Fitzgerald Global Healthcare Conference
Nyxoah to Participate in Upcoming Investor ConferencesNyxoah to Participate in Upcoming Investor Conferences
Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023
Nyxoah to Participate in the 43rd Canaccord Genuity Growth ConferenceNyxoah to Participate in the 43rd Canaccord Genuity Growth Conference
Nyxoah Appoints Christoph Eigenmann as Chief Commercial OfficerNyxoah Appoints Christoph Eigenmann as Chief Commercial Officer
Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023Nyxoah to Release First Quarter 2023 Financial Results on May 16, 2023
